The Russian pharmaceutical manufacturers advocated the introduction of a separate accelerated track for registration and market entry of Russian innovations. During the workshop meeting "Applied tools for ensuring the accessibility of innovative treatment: from financial models to clinical practice" at the "Right to Health" Congress, the issue of the possibility of creating a separate track for domestic innovations so that they reach the Russian patient quickly was considered. Representatives of the pharmaceutical community believe that fast tracks can be used for this, and it is also worth trying to synchronize clinical and regulatory procurement processes - currently, the inclusion of drugs in the VED lists and the VZN programs are isolated from each other and are not coordinated. It is believed that processes should be accelerated as much as possible. Natalya Radonenko, Deputy Commercial Director, Director of Ensuring Access to the Pharmaceutical Market at Pharmstandard Group of Companies: "The Russian pharmaceutical industry has moved into a new era of innovative development. And this technological breakthrough revealed a number of difficulties. From the moment the drug is registered until it enters the market, it takes a key track of 3 years for one problem. Medicine Through the main regulatory and economic stages it is necessary to create a separate track for local innovations so that they reach the Russian patient faster. Vice President of Corporate Communications of NPO Petrovax Pharm LLC Kirill Danishevsky insists that it is necessary to introduce a fast track to the development of the technological leadership of the pharmaceutical industry. "The Russian pharmaceutical industry is not equivalent to international pharmaceuticals. We operate at 2-3% of the market, while companies pay loans of 12-15% per year. We cannot dilute the risks. Moreover, in Russia they require localization.

The Russian pharmaceutical manufacturers advocated the introduction of a separate accelerated track for registration and market entry of Russian innovations. During the workshop meeting "Applied tools for ensuring the accessibility of innovative treatment: from financial models to clinical practice" at the "Right to Health" Congress, the issue of the possibility of creating a separate track for domestic innovations so that they reach the Russian patient quickly was considered. Representatives of the pharmaceutical community believe that fast tracks can be used for this, and it is also worth trying to synchronize clinical and regulatory procurement processes - currently, the inclusion of drugs in the VED lists and the VZN programs are isolated from each other and are not coordinated. It is believed that processes should be accelerated as much as possible. Natalya Radonenko, Deputy Commercial Director, Director of Ensuring Access to the Pharmaceutical Market at Pharmstandard Group of Companies: "The Russian pharmaceutical industry has moved into a new era of innovative development. And this technological breakthrough revealed a number of difficulties. From the moment the drug is registered until it enters the market, it takes a key track of 3 years for one problem. Medicine Through the main regulatory and economic stages it is necessary to create a separate track for local innovations so that they reach the Russian patient faster. Vice President of Corporate Communications of NPO Petrovax Pharm LLC Kirill Danishevsky insists that it is necessary to introduce a fast track to the development of the technological leadership of the pharmaceutical industry. "The Russian pharmaceutical industry is not equivalent to international pharmaceuticals. We operate at 2-3% of the market, while companies pay loans of 12-15% per year. We cannot dilute the risks. Moreover, in Russia they require localization.